Morgan Stanley Icosavax, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$5.95 - $15.79 $391,527 - $1.04 Million	65,803 New	65,803 $1.04 Million
Q4 2023 Feb 13, 2024	BUY	$5.95 - $15.79 $185,747 - $492,932	31,218 Added 90.26%	65,803 $1.04 Million
Q3 2023 Nov 15, 2023	BUY	$7.22 - $10.05 $20,266 - $28,210	2,807 Added 8.83%	34,585 $268,000
Q2 2023 Aug 14, 2023	BUY	$4.89 - $10.57 $36,376 - $78,630	7,439 Added 30.56%	31,778 $315,000
Q1 2023 May 15, 2023	BUY	$5.62 - $11.51 $20,602 - $42,195	3,666 Added 17.73%	24,339 $141,000
Q4 2022 Feb 14, 2023	BUY	$2.32 - $10.97 $3,310 - $15,654	1,427 Added 7.41%	20,673 $164,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $9.21 $294,625 - $878,155	-95,348 Reduced 83.21%	19,246 $61,000
Q2 2022 Oct 27, 2022	BUY	$5.7 - $10.33 $398,236 - $721,715	69,866 Added 156.2%	114,594 $657,000
Q2 2022 Aug 15, 2022	BUY	$5.7 - $10.33 $398,236 - $721,715	69,866 Added 156.2%	114,594 $657,000
Q1 2022 Oct 27, 2022	SELL	$4.41 - $22.5 $308,109 - $1.57 Million	-69,866 Reduced 60.97%	44,728 $315,000
Q1 2022 May 13, 2022	BUY	$4.41 - $22.5 $15,408 - $78,615	3,494 Added 8.47%	44,728 $315,000
Q4 2021 Feb 14, 2022	BUY	$21.07 - $34.98 $112,513 - $186,793	5,340 Added 14.88%	41,234 $944,000
Q3 2021 Nov 15, 2021	BUY	$24.85 - $40.25 $891,965 - $1.44 Million	35,894 New	35,894 $1.06 Million

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.